Tel. : 01 45 33 67 17 / E-mail : coger@coger.fr
AVANTI POLAR LIPIDS , CYGNUS , LARODAN , ADIPOGEN , MYBIOSOURCE , SERVA NORDMARK, BIOWORLD, EDGEBIO , PANREAC APPLICHEM
Ajouter au panier
Le produit a été ajouté au panier Le stock est insuffisant. unités ont été rajoutées au panier Total:
|
Stock épuisé.
En rupture de stock
|
Quantité minimum d'achat
La quantité minimum d'achat n'est pas atteinte
|
photos non contractuelles
Product description: Recombinant Antibody. This antibody reacts to human p44/42 MAPK (Erk1/2) only when phosphorylated at Thr202 and Tyr204. There is no cross-reactivity to Erk1/2 that is not phosphorylated. This antibody may also react to mouse or rat Phospho- Erk1/2 (Thr203/Tyr205) as predicted by immunogen homology. Applications: IHC, WB. Clone: RM451. Isotype: Rabbit IgG. Formulation: Liquid. 50% Glycerol/PBS with 1% BSA and 0.09% sodium azide. Extracellular signal-regulated kinases 1 and 2 (also known as ERK1/2, p44/42, or MAPK3/1) belong to a family of conserved serine/threonine protein kinases known as mitogen-activated protein kinases (MAPKs) that are involved in many cellular programs such as proliferation, differentiation, motility and survival. The ERK1/2 signaling pathway can be activated in response to a diverse range of extracellular stimuli including mitogens, growth factors and cytokines. The primary activators of ERK1/2 are MEK1 and MEK2 which activate p44 and p42 through phosphorylation of activation loop residues Thr202/Tyr204 and Thr185/Tyr187 in ERK1 and ERK2, respectively. Several downstream targets of ERK1/2 have been identified, including p90RSK and the transcription factor Elk-1. ERK1/2 are negatively regulated by MAPK phosphatases as well as by chemical inhibitors of MEK. The ERK pathway is disrupted in many types of cancer and thus is an important target for diagnosis and treatment.
Alerte
Veuillez saisir les champs obligatoires! |